A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors

Asha Nayak,Zhonglin Hao,Ramses Sadek,Nicholas Vahanian, W Jay Ramsey,Eugene Kennedy,Mario Mautino,Charles Link,Pamela Bourbo,Robin Dobbins,Kelly Adams, Allison Diamond,Lisa Marshall,David H Munn,John Janik,Samir N Khleif

Journal for ImmunoTherapy of Cancer（2014）

Cited 19|Views12

No score

Abstract

Meeting abstracts Clinical Trial Registration Number: [NCT02048709][1] The enzyme Indoleamine 2,3-dioxygenase (IDO1) catalyzes the cleavage of L-tryptophan, resulting in the production of kynurenine. Tryptophan depletion and kynurenine metabolites enhance the number and function of Tregs (

Translated text

Key words

Dose Level, Ipilimumab, Kynurenine, Advanced Solid Tumor, Clinical Trial Registration

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined